
Warning to parents after baby girl grows 'micropenis' from lying on dad's chest
Parents have been issued a warning after a baby girl grew a 'micropenis' from lying on her father's chest. The Swedish youngster's unusual development came after repeated skin-to-skin contact with her dad.
New mothers have long been encouraged to go skin-to-skin with their babies in the moments after they are born. This can help regulate the baby's breathing and heart rate, boost the mother's milk supply, and help with bonding and more.
In recent years, the advice has extended to fathers too, as it can help lower their stress levels while also helping form an early connection between the dad and baby.
This Swedish father had been having skin-to-skin contact with his little girl throughout her short life so far, having her lying on his chest.
The issue arose, however, due to his own medication. He had been applying a testosterone gel to his skin, which then made extreme changes to his 10-month-old daughter's genitalia.
Testosterone gel is a treatment often used by men whose bodies don't produce enough of the hormone naturally. But those who use it should be careful of exposing others to the hormone.
The baby was repeatedly exposed to testosterone through her father's bare skin and led to her clitoris growing longer, resembling a tiny penis, and her labia fusing together into what looked like a small male scrotum.
Although the growth has been dubbed a 'micropenis', Swedish doctors have stated that this specific term refers to underdeveloped male genitalia, and not the abnormal situation at hand which was caused by the hormone treatment.
And medics have issued a warning to parents about going skin-to-skin while using medication that could foster unexpected changes to their child's body.
Hormone treatments involve using hormones or hormone-blocking medications to address various medical conditions, primarily cancer and menopause symptoms.
Hormone therapy can either replace deficient hormones, like in hormone replacement therapy (HRT) for menopause, or block the action of certain hormones.
The baby's parents were shocked to notice the changes in their baby's body, and subsequent blood tests found she had unusually high levels of testosterone in her blood.
Once the couple knew the source of the changes to their daughter's body, they stopped exposing her to the treatment. When she was no longer being exposed to testosterone, the baby's elongated genitalia began to retract back to normal.
LadBible reports that while this case occurred eight years ago, doctors have seen a handful of similar cases in the time since.
Professor Jovanna Dahlgren, paediatric expert at Sahlgrenska University Hospital in Gothenburg in Sweden, said there have been at least six similar cases that she knows of.
She is urging parents to remain vigilant with their kids, especially if they are using hormone treatments, due to the risks exposure can pose to their early development.
She said to Swedish Newspaper Göteborgs-Posten: "I don't think people always understand how potent these treatments are. The parents become completely desperate when they understand what has happened."
And it's not just testosterone that can change the bodies of baby girls, but female hormone treatments can have similar effects on boys.
One case involved a 10-year-old boy who grew breasts after being exposed to a female hormone treatment that was being taken by his mother.
This phenomenon can also occur in newborn males who sometimes see breast enlargement due to being exposed to oestrogen by their mothers, but this usually goes away after two to six months.
Join the Daily Record WhatsApp community!

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


North Wales Chronicle
6 days ago
- North Wales Chronicle
AstraZeneca unveils plans for £37bn investment in US amid tariff threats
The Cambridge-headquartered firm said the investment will fund a new 'state-of-the-art' manufacturing facility in Virginia – set to be its largest single manufacturing investment in the world. It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas. The announcement marks the latest by a global pharmaceutical giant to expand its footprint in the US as Mr Trump has threatened to impose tariffs of up to 20% on drug imports in an effort to increase manufacturing in America and drive down costs for Americans. AstraZeneca said the mammoth investment will create tens of thousands of jobs across the US, 'powering growth and delivering next-generation medicines for patients in America and worldwide'. The Anglo-Swedish group, which is listed on the FTSE 100, said the investment will also help it towards the group's target of reaching 80 billion US dollars (£59.4 billion) in revenues by 2030. Half of this is expected to come from the US, it added. Pascal Soriot, chief executive of AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.' Despite being headquartered in the UK, America is AstraZeneca's largest market, where it employs more than 18,000 staff and makes 42% of total group sales. It already has 19 R&D, manufacturing and commercial sites across the country. The new factory planned for Virginia will produce drug substances for the company's weight management and metabolic portfolio, it said. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. 'President Trump and our nation's new tariff policies are focused on ending this structural weakness. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores.'

Leader Live
6 days ago
- Leader Live
AstraZeneca unveils plans for £37bn investment in US amid tariff threats
The Cambridge-headquartered firm said the investment will fund a new 'state-of-the-art' manufacturing facility in Virginia – set to be its largest single manufacturing investment in the world. It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas. The announcement marks the latest by a global pharmaceutical giant to expand its footprint in the US as Mr Trump has threatened to impose tariffs of up to 20% on drug imports in an effort to increase manufacturing in America and drive down costs for Americans. AstraZeneca said the mammoth investment will create tens of thousands of jobs across the US, 'powering growth and delivering next-generation medicines for patients in America and worldwide'. The Anglo-Swedish group, which is listed on the FTSE 100, said the investment will also help it towards the group's target of reaching 80 billion US dollars (£59.4 billion) in revenues by 2030. Half of this is expected to come from the US, it added. Pascal Soriot, chief executive of AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.' Despite being headquartered in the UK, America is AstraZeneca's largest market, where it employs more than 18,000 staff and makes 42% of total group sales. It already has 19 R&D, manufacturing and commercial sites across the country. The new factory planned for Virginia will produce drug substances for the company's weight management and metabolic portfolio, it said. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. 'President Trump and our nation's new tariff policies are focused on ending this structural weakness. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores.'


South Wales Guardian
6 days ago
- South Wales Guardian
AstraZeneca unveils plans for £37bn investment in US amid tariff threats
The Cambridge-headquartered firm said the investment will fund a new 'state-of-the-art' manufacturing facility in Virginia – set to be its largest single manufacturing investment in the world. It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas. The announcement marks the latest by a global pharmaceutical giant to expand its footprint in the US as Mr Trump has threatened to impose tariffs of up to 20% on drug imports in an effort to increase manufacturing in America and drive down costs for Americans. AstraZeneca said the mammoth investment will create tens of thousands of jobs across the US, 'powering growth and delivering next-generation medicines for patients in America and worldwide'. The Anglo-Swedish group, which is listed on the FTSE 100, said the investment will also help it towards the group's target of reaching 80 billion US dollars (£59.4 billion) in revenues by 2030. Half of this is expected to come from the US, it added. Pascal Soriot, chief executive of AstraZeneca, said: 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.' Despite being headquartered in the UK, America is AstraZeneca's largest market, where it employs more than 18,000 staff and makes 42% of total group sales. It already has 19 R&D, manufacturing and commercial sites across the country. The new factory planned for Virginia will produce drug substances for the company's weight management and metabolic portfolio, it said. Howard Lutnick, US Secretary of Commerce, said: 'For decades Americans have been reliant on foreign supply of key pharmaceutical products. 'President Trump and our nation's new tariff policies are focused on ending this structural weakness. 'We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores.'